Search
lasmiditan (Reyvow)
Indications:
- treatment of migraine (FDA-approved Oct 2019)
Contraindications:
- not indicated for prevention of migraine
- second dose not effective foor same migraine
- not recommended for Child-Pugh class C cirrhosis
Dosage:
- 50, 100, or 200 mg PO PRN
* not to exceed 1 dose/24 hours
Dosage adjustment in renal failure:
- none
Adverse effects:
- minimal cardiovascular effects
- sleepiness, dizziness, fatigue, paresthesia, sedation, muscle weakness
- impaired driving (8 hr between dosing & driving or operating machinery)
- nausea (lumped with neurological adverse effects [3])
Mechanism of action:
- serotonin agonist selective for the 5-HT1F receptor
Notes:
- phase III trials June 2018
Interactions
drug adverse effects of triptan(s)
General
serotonin agonist (5-HT receptor agonist, triptan)
neurologic agent
Database Correlations
PUBCHEM correlations
References
- Highleyman L.
Lasmiditan Provides Rapid Migraine Relief. First-in-class drug
promises efficacy without cardiovascular side effects.
MedPage Today. July 02, 2018
https://www.medpagetoday.com/meetingcoverage/ahs/73804
- Wietecha L, et al
Phase 3 studies (SAMURAI, SPARTAN) of lasmiditan compared to
placebo for acute treatment of migraine.
American Headache Society (AHS) 2018; Abstract IOR-02.
- Maassen van den Brink A, et al
Lasmiditan inhibits CGRP release in the mouse trigeminovascular
system.
American Headache Society (AHS) 2018; Abstract OR-03.
- FDA News Release. Oct 11, 2019
FDA approves new treatment for patients with migraine
https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-patients-migraine
- Windle ML
Rapid Rx Quiz: Headache Medications
Medscape. Sept 12, 2022
https://reference.medscape.com/viewarticle/980181
- Medscape: lasmiditan (Rx)
https://reference.medscape.com/drug/reyvow-lasmiditan-1000310